NVP-BEZ235 overcomes gefitinib-acquired resistance by down-regulating PI3K/AKT/mTOR phosphorylation

BACKGROUND: Patients harboring activating mutations in epidermal growth factor receptors (EGFR) are particularly sensitive to EGFR tyrosine kinase inhibitors (TKIs). However, most patients develop an acquired resistance after a period of about 10 months. This study focuses on the therapeutic effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Zhihua, Li, Qiuhui, Zhang, Sheng, Chen, Jing, Huang, Lili, Ren, Jinghua, Chang, Yu, Liang, Yichen, Wu, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4321659/
https://www.ncbi.nlm.nih.gov/pubmed/25674002
http://dx.doi.org/10.2147/OTT.S62128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4321659/
https://www.ncbi.nlm.nih.gov/pubmed/25674002
http://dx.doi.org/10.2147/OTT.S62128

Ejemplares similares